Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

(2021) John Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

New targeted approaches for epigenetic age predictions

(2020) Yang Han et al.   BMC BIOLOGY

JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

(2020) Tracy Dagher et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Methylation age as a correlate for allele burden, disease status and clinical response in myeloproliferative neoplasm patients treated with Vorinostat

(2019) S. McPherson et al.   EXPERIMENTAL HEMATOLOGY

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

(2018) Maria Kleppe et al.   CANCER CELL

Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies

(2018) Steve Horvath et al.   Aging-US

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner

(2016) Robin E. Frink et al.   Oncotarget

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

(2015) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

(2015) Gabriela M. Baerlocher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aging of blood can be tracked by DNA methylation changes at just three CpG sites

(2014) Carola Weidner et al.   GENOME BIOLOGY

DNA methylation age of human tissues and cell types

(2013) Steve Horvath   GENOME BIOLOGY

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL–positive CML cells

(2010) Ute Brassat et al.   EXPERIMENTAL HEMATOLOGY